Date:1/26/2010

e EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008.  Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Important Additional Information: 

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of Chattem. The tender offer is being made pursuant to a Tender Offer Statement on Schedule TO, containing an offer to purchase, form of letter of transmittal and related tender offer documents, filed by River Acquisition Corp. and sanofi-aventis with the U.S. Securities and Exchange Commission (the "SEC") on January 11, 2010.   Chattem filed a Solicitation/Recommendation Statement on Schedule 14D-9 relating to the tender offer with the SEC on January 11, 2010.  Sanofi-aventis and Chattem have mailed these documents to all Chattem shareholders of record.  These documents, as they may be amended from time to time, contain important information about the tender offer
'/>"/>

SOURCE Sanofi-aventis Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
2. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
3. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
4. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
5. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
8. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
9. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market